ZYMEWORKS INC. (ZYME) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 91.66%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 91.66% | Share-based compensation / revenue. Period ending 2026-06-30. $34.03M ÷ $37.13M × 100 ≈ 91.66% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 37.13M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 34.03M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -155.56M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $37.13M | $34.03M | $-155.56M | (m) | (m) | 91.66% | (m) | (m) |
| 2026-03-31 | (m) | $81.26M | $28.57M | $-114.05M | (m) | (m) | 35.15% | (m) | (m) |
| 2025-12-31 | (m) | $105.97M | $28.03M | $-92.55M | (m) | (m) | 26.46% | (m) | (m) |
| 2025-09-30 | (m) | $134.48M | $24.20M | $-70.61M | (m) | (m) | 18.00% | (m) | (m) |
| 2025-06-30 | (m) | $122.87M | $21.96M | $-82.71M | (m) | (m) | 17.87% | (m) | (m) |
| 2025-03-31 | (m) | $93.38M | $20.64M | $-124.92M | (m) | (m) | 22.10% | (m) | (m) |
| 2024-12-31 | (m) | $76.30M | $17.79M | $-137.11M | (m) | (m) | 23.32% | (m) | (m) |
| 2024-09-30 | (m) | $62.20M | $16.14M | $-138.31M | (m) | (m) | 25.95% | (m) | (m) |
| 2024-06-30 | (m) | $62.70M | $13.52M | $-137.35M | (m) | (m) | 21.56% | (m) | (m) |
| 2024-03-31 | $129.75M | $50.46M | $9.33M | $-148.57M | (m) | 257.11% | 18.49% | (m) | (m) |
| 2023-12-31 | $143.62M | $76.01M | $8.10M | $-138.05M | (m) | 188.94% | 10.66% | (m) | (m) |
| 2023-09-30 | $171.06M | $461.58M | $9.23M | $204.76M | (m) | 37.06% | 2.00% | (m) | (m) |
| 2023-06-30 | $175.38M | $447.70M | $11.99M | $187.64M | (m) | 39.17% | 2.68% | (m) | (m) |
| 2023-03-31 | $192.00M | $446.14M | $14.52M | $175.93M | (m) | 43.03% | 3.25% | (m) | (m) |
| 2022-12-31 | $208.60M | $412.48M | $4.01M | $130.53M | (m) | 50.57% | 0.97% | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $199.75M | $26.68M | $10.76M | $-215.63M | (m) | 748.70% | 40.31% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $171.20M | $38.95M | $29.12M | $-187.47M | (m) | 439.53% | 74.75% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |